Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year
06:55am, Tuesday, 03'rd Feb 2026
Merck's stock falls as the full-year revenue and profit outlooks were below expectations.
Merck Earnings Top Estimates. Why the Stock Is Falling.
06:48am, Tuesday, 03'rd Feb 2026
Merck says 2026 earnings will take a hit due to its pending takeover of Cidara Therapeutics.
Merck Expects Slower Earnings Growth As It Spends on Acquisitions
06:38am, Tuesday, 03'rd Feb 2026
Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.
Merck forecasts 2026 sales below estimates on patent losses
06:34am, Tuesday, 03'rd Feb 2026
Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will hit harder than analysts are proje
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
06:31am, Tuesday, 03'rd Feb 2026
Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that f
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results.
Market Indexes Bounce Back to Start a New Trading Week
06:51pm, Monday, 02'nd Feb 2026
Improved Manufacturing data joined another strong tranche of Q4 earnings reports today.
Market Today: Palantir beats, Disney warns; oil slides
05:35pm, Monday, 02'nd Feb 2026
Guru Stock PicksSteven Romick has made the following transactions:Reduce in ADI by 5.61%Sold out in XSWX:AMRZAdd in FBIN by 19.9%New position in TMOYacktman Fun
Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year
11:40am, Monday, 02'nd Feb 2026
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
11:25am, Monday, 02'nd Feb 2026
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Wall Street Week Ahead
07:03am, Sunday, 01'st Feb 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Merck (MRK) Advances While Market Declines: Some Information for Investors
06:46pm, Friday, 30'th Jan 2026
Merck (MRK) reached $110.42 at the closing of the latest trading day, reflecting a +1.92% change compared to its last close.
Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
08:51am, Friday, 30'th Jan 2026
Merck heads into Q4 earnings with strong Keytruda demand and new product launches, but declining estimates and M&A costs cloud the near-term outlook.
Why the Market Dipped But Merck (MRK) Gained Today
06:50pm, Thursday, 29'th Jan 2026
Merck (MRK) closed at $108.34 in the latest trading session, marking a +1.35% move from the prior day.
Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:15am, Thursday, 29'th Jan 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarte
